الفهرس 
Aim of The WorkOnly 14 pages are availabe for public view
 |  | from | 97 |  |  |
| | | from | 97 | | |
Abstract
Central retinal vein occlusion is a common retinal disorder that usually affects individuals ≥55 of age.
ANTI -VEGF therapy has become the initial treatment of choice for patients with macular edema secondary to central retinal vein occlusion. Optical coherence tomography image resolution allow retinal architecture to be visualized in great detail.
In this study we compare between intravitreal injection of Anti-Vascular Endothelial Growth Factors versus systemic anticoagulant with intravitreal injection of Anti-Vascular Endothelial Growth Factors in the treatment of central retinal vein occlusion.
Optical coherent tomography is used to evaluate macular thickness at baseline and in follow up as aresponse for treatment.
Our Study included 30 patients with central retinal vein occlusion.
Patients divided into two groups, first group treated by there successive intravitreal injection of Anti-Vascular Endothelial Growth Factors (Ranibizumab) one month apart. Second group treated by the same protocol of injection of first group combined with systemic anticoagulant.
The two groups compred according to improvement in BCVA as a functional response and improvement in central macular thickness as anatomical response. Visual gains after treatment may be strongly influenced by factors such as extent of ischemic macular damage, retinal pigment epithelium atrophic changes, and progressive apoptotic cell death.